AstraZeneca unbranded effort urges sufferers to "Rethink COPD"

Share this article:
AstraZeneca unbranded effort urges sufferers to "Rethink COPD"
AstraZeneca unbranded effort urges sufferers to "Rethink COPD"
AstraZeneca is rolling out an unbranded COPD education campaign featuring comedian and actor Robert Klein.

The campaign, dubbed RethinkCOPD, is aimed at getting sufferers to consider their options with respect to diet, exercise and, of course, medication.

“For a lot of these patients, it's really about getting through their day,” said senior brand communications manager Dana Settembrino. “It's a struggle to get out of bed in the morning, it's a struggle to brush their teeth, and they want to be independent. It's all about getting them to talk to their doctor and start to think differently about this condition. There's not a lot known about it, and there's a stigma associated with it because most people have gotten it from smoking.”

Klein, a 67-year-old Bronx-born performer whose career has spanned Broadway roles and HBO comedy specials, features on the campaign's website (www.RethinkCOPD.com), where he'll discuss his diagnosis and the steps he's taken to keep his COPD in check. The campaign also features 15-second broadcast PSAs aimed at driving traffic to the Website.

The tagline of the aspirational campaign is “People with COPD are expecting more.” AstraZeneca worked with agencies Edelman, Cadient and Digitas Health on it.

The company's Symbicort, indicated for COPD as well as asthma, is not mentioned in the effort.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.